Junhua Zheng/ Wei Zhai Team Develops Multimodal AI Model for Kidney Cancer, Published in a Nature Sub-Journal

Junhua Zheng/ Wei Zhai Team Develops Multimodal AI Model for Kidney Cancer, Published in a Nature Sub-Journal

Recently, the urology team led by Prof. Junhua Zheng and Researcher Wei Zhai from the Department of Urology, Renji Hospital, Shanghai Jiao Tong University School ofkk Medicine, together with multiple collaborating centers, achieved a major breakthrough in precision prognosis of kidney cancer. Their multimodal prediction of recurrence score (MPRS) model was successfully published in npj Digital Medicine, a leading global digital medicine journal under the Nature portfolio. This model provides crucial support for recurrence-risk assessment and individualized treatment in patients with clear cell renal cell carcinoma (ccRCC).
CCHIO Leadership Dialogue | Prof. Changling Li: From “Following” to “Leading” — China’s Global Breakthroughs and New Directions in Precision Urologic

CCHIO Leadership Dialogue | Prof. Changling Li: From “Following” to “Leading” — China’s Global Breakthroughs and New Directions in Precision Urologic

From November 6–9, 2025, the China Congress of Holistic Integrative Oncology (CCHIO 2025) was held in Kunming. The conference was hosted by the China Anti-Cancer Association (CACA) and the Tengchong Scientist Forum Organizing Committee, co-organized by the World Association of Integrative Oncology (WAIO) and the China Academy of Integrative Medicine, and jointly undertaken by Yunnan Cancer Hospital, Kunming Medical University, and the Yunnan Anti-Cancer Association. As urologic cancers remain among the most common malignancies worldwide, advances in this field drew substantial attention at CCHIO 2025. Oncolgy  Frontier– Urology Frontier invited Prof. Changling Li, Executive Chair of the CACA Committee on Integrative Urologic Oncology and Chair of the CACA Urologic Oncology Committee, to share insights on integrative oncology, China’s recent breakthroughs, and future directions.
Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

With China’s population undergoing demographic aging and growing public awareness of cancer screening, the clinical need for the management of urologic malignancies is steadily increasing. Radiotherapy, a mainstay of oncologic treatment, has evolved rapidly—progressing from old techniques to intensity‑modulated radiotherapy (IMRT), and from conventional fractionation regimens to stereotactic body radiation therapy (SBRT). Precision radiotherapy is now emerging as a pivotal modality in the management of urologic cancers. Professor Ningning Lu, affiliated to the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, has dedicated years to the field of precision radiotherapy for urologic tumors, amassing substantial clinical expertise and a robust research portfolio. UroStream invited Professor Lu to deliver an in-depth review of the clinical applications of precision radiotherapy in urologic malignancies, thereby providing evidence-based insights and practical guidance for clinicians.
Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma 

Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma 

With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University Cancer Center delivered a keynote lecture titled “Rational Reflections Amid the Surge of Immunotherapy in RCC.” After the session, Oncology Frontier – Urology Frontier invited Prof. Dong for an in-depth discussion on the evolving role of neoadjuvant therapy, adjuvant immunotherapy, and precision strategies for FH-deficient RCC.